CMS Grants Fresenius Kabi COVID-19 Codes for Tyenne® (tocilizumab-aazg)

New HCPCS codes will support billing and reimbursement for Tyenne in COVID-19 treatment

Apr. 10, 2026 at 6:06am

Got story updates? Submit your updates here. ›

A glowing, neon outline of a syringe or IV drip against a dark background, conceptually representing the medical technology and electricity of a COVID-19 treatment.New coding for Tyenne will streamline access to a critical COVID-19 treatment option.Lake Zurich Today

Fresenius Kabi announced that the Centers for Medicare & Medicaid Services has issued indication-specific Healthcare Common Procedure Coding System (HCPCS) codes for Tyenne® (tocilizumab-aazg) for the treatment of COVID-19. The new codes will be effective for Medicare claims for eligible patients administered Tyenne on April 1, 2026.

Why it matters

The new COVID-19 HCPCS codes will help facilitate efficient claims processing and reinforce Fresenius Kabi's commitment to ensuring patients have access to important treatment options for COVID-19.

The details

The new codes - Q0238 for injection, M0233 for intravenous infusion first-dose, and M0234 for intravenous infusion second-dose - will support billing and reimbursement for Tyenne when used in the treatment of COVID-19 in appropriate patients, consistent with its FDA-approved labeling. Tyenne previously received a permanent, product-specific Q-code for its approved autoimmune indications.

  • The new COVID-19 HCPCS codes will be effective for Medicare claims for eligible patients administered Tyenne on April 1, 2026.

The players

Fresenius Kabi

A part of Fresenius and a leading provider of essential medicines and medical technologies.

Centers for Medicare & Medicaid Services

The federal agency that administers the Medicare program and works in partnership with state governments to administer Medicaid.

Tyenne® (tocilizumab-aazg)

A prescription medicine called an Interleukin-6 (IL-6) receptor antagonist, developed by Fresenius Kabi as a biosimilar to Actemra® (tocilizumab).

Got photos? Submit your photos here. ›

What they’re saying

“Fresenius Kabi's indication-specific codes for COVID-19 represent an important step in supporting provider access and streamlined reimbursement for Tyenne.”

— Molly Benson, Senior Vice President, Biopharma, at Fresenius Kabi USA

The takeaway

The new COVID-19 HCPCS codes for Tyenne will help ensure patients have access to this important treatment option by facilitating efficient claims processing and reimbursement for healthcare providers.